ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
Zim Laboratories confirmed that its subsidiary, ZIM FZE, completed the previously announced AED 9,16,000 investment in its step-down subsidiary, ZIM Scientific Office LLC.
Zim Laboratories reported 31.2% YoY revenue growth in Q1 FY27, driven by core pharma and exports (84% of income). Strategy focuses on EU-GMP remediation and expanding the innovation-led NIP/OTF portfolio.
Q1 FY27 Total Operating Income rose 31.2% YoY to ₹942 Mn. However, EBITDA fell 40% to ₹34 Mn due to utility/employee costs.
Zim Laboratories Ltd reported revenue from operations of ₹94.2 Cr (+31.2% YoY) and a net loss of ₹4 Cr for Q1 FY27.
Zim Laboratories reported FY26 revenue of ₹3,744M, flat YoY, impacted by geopolitical issues in the MENA region and EU GMP constraints. Strategy focuses on remediation and transitioning from R&D to execution.
Zim Laboratories reported FY26 revenue of ₹3,744 Mn with 11.1% EBITDA margin. Strategy shifts towards innovative products (NIP/OTF) despite regulatory headwinds and geopolitical logistics challenges.
Zim Laboratories Ltd reported revenue from operations of ₹105.3 Cr (-3.1% YoY) and net profit of ₹3.7 Cr (-24.5% YoY) for Q4 FY26.